GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

NRX Pharmaceuticals NRXP · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.38

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$1.2m

FY2017FY2025

Net income

−$28.6m

FY2017FY2025

Free cash flow

−$14.1m

FY2017FY2025

Shareholders' equity

−$15.9m

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$1.2m————————
Gross profit$720,000−$5,000−$5,000−$4,000−$2,000−$2,000—−$1.0m—
Research and development$3.8m$6.2m$13.4m$17.0m$20.3m$10.6m$3,496——
Operating income−$28.0m−$24.0m−$27.6m−$44.3m−$95.2m−$51.7m−$713,187−$1.0m−$134,480
Net income−$28.6m−$25.1m−$30.1m−$39.8m−$93.1m−$51.8m$408,427$66,101−$105,000
Diluted earnings per share-0.90-2.39-0.36-0.60-1.80-7.660.790.02-0.06

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$13.0m$3.7m$7.3m$25.8m$32.7m$2.9m$32.1m$70.8m$69.6m
Cash and short-term investments$7.8m$1.4m$4.6m$20.1m$27.6m$1.9m$6$11,079$449,374
Total liabilities$28.9m$26.9m$19.0m$18.4m$11.9m$46.7m$2.6m$1.3m$93,171
Debt$631,000$6.6m$9.2m$10.5m$518,000$797,000$2.0m$690,000—
Shareholders' equity−$15.9m−$23.2m−$11.7m$7.4m$20.8m−$43.8m$29.5m$69.5m$69.5m
Shares outstanding32m11m84m66m52m7m1m3m2m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$14.1m−$10.6m−$21.7m−$39.8m−$37.7m−$2.3m−$792,731−$473,187−$135,807
Capital spending——−$3,000−$10,000−$7,000−$2,000−$1——
Free cash flow−$14.1m−$10.6m−$21.7m−$39.8m−$37.7m−$2.3m−$792,732−$473,187−$135,807

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$1.1m$1.1m$983,000$242,000—$4,000$4,000—
Gross profit$258,000$272,000$475,000$104,000—$2,000−$1,000−$2,000
Operating income−$6.5m−$4.7m$1.0m−$4.1m−$3.7m−$3.8m−$3.6m−$3.0m
Net income−$16.5m−$1.4m$360,000−$5.9m−$17.6m−$5.5m−$9.1m−$1.6m
Diluted earnings per share-0.44-0.040.01-0.19-0.55-0.17-0.86-0.15
Cash from operations−$8.0m−$4.0m−$3.0m−$2.0m−$4.0m−$3.0m−$2.0m−$2.0m
Total assets$34.2m$11.9m$13.0m$15.0m$4.8m$7.6m$3.7m$4.5m
Cash and short-term investments$26.7m$6.7m$7.8m$7.2m$2.9m$5.5m$1.4m$1.6m
Debt$790,000$391,000$316,000$10.3m$10.2m$8.4m$6.6m$6.7m
Shareholders' equity−$170,000−$13.8m−$15.9m−$25.8m−$35.6m−$25.2m−$23.2m−$18.8m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-14.3%-11.6%—
Net income-10.4%-11.2%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2017
Price to earnings-3.0-0.9-12.8-18.6-11.1-13.355.9-728.1
Price to sales70.2———————

Share price return

Finished calendar years

202520242023202220212020201920182017
Return41%-60%-64%-51%-79%133%4%5%1%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 2 Apr 2024
  • 1-to-1 reverse split · 25 May 2021

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.